ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference

08 фев 2023 08:00:01 Источник Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 фев 2023 16:09:57 Источник Nasdaq GlobeNewswire

Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis

14 янв 2023 04:00:00 Источник Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 янв 2023 16:00:00 Источник Nasdaq GlobeNewswire

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age

19 дек 2022 08:00:00 Источник Nasdaq GlobeNewswire

Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older

12 дек 2022 08:00:53 Источник Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 дек 2022 16:01:00 Источник Nasdaq GlobeNewswire

Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255

05 дек 2022 08:00:00 Источник Nasdaq GlobeNewswire

Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology

28 ноя 2022 08:00:01 Источник Nasdaq GlobeNewswire

Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report

21 ноя 2022 09:15:00 Источник Nasdaq GlobeNewswire

CORRECTION -- Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older

15 ноя 2022 11:09:55 Источник Nasdaq GlobeNewswire

Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older

15 ноя 2022 08:00:02 Источник Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

11 ноя 2022 08:00:00 Источник Nasdaq GlobeNewswire

Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update

08 ноя 2022 16:02:00 Источник Nasdaq GlobeNewswire

Arcutis to Report Third Quarter Financial Results

25 окт 2022 16:05:00 Источник Nasdaq GlobeNewswire

Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis

21 окт 2022 08:00:00 Источник Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 окт 2022 16:00:00 Источник Nasdaq GlobeNewswire

Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body Psoriasis

26 сен 2022 08:00:02 Источник Nasdaq GlobeNewswire

Journal of the American Medical Association Publishes Roflumilast Cream 0.3% Results from Pivotal DERMIS-1 and -2 Phase 3 Trials in Plaque Psoriasis

20 сен 2022 11:07:40 Источник Nasdaq GlobeNewswire

New Data from Arcutis’ STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) Congress

09 сен 2022 08:15:00 Источник Nasdaq GlobeNewswire